1. Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma
- Author
-
Lee, Po-Hsin, Chiang, Chun-Ju, Tseng, Jeng-Sen, Zheng, Zhe-Rong, Chen, Kun-Chieh, Chu, Cheng-Hsiang, Huang, Yen-Hsiang, Hsu, Kuo-Hsuan, Lee, Wen-Chung, Yang, Tsung-Ying, Liu, Tsang-Wu, Hsia, Jiun-Yi, and Chang, Gee-Chen
- Subjects
Cancer Research ,Oncology - Abstract
IntroductionFor patients with T2aN0 stage IB lung adenocarcinoma, benefits of adjuvant chemotherapy remain controversial. Here, we aimed to evaluate such benefits.MethodsThis retrospective cohort study was conducted on the database of the National Taiwan Cancer Registry. We analyzed patients with T2aN0 stage IB lung adenocarcinoma (re-classified by AJCC 8th edition) diagnosed during the period from January 2011 to December 2017. They were divided into two groups: (1) group 1: tumor 3 cm, but ResultsA total of 2,100 patients with T2aN0 stage IB lung adenocarcinoma (1,265 in group 1 and 835 in group 2) were enrolled for study. The proportions of patients receiving adjuvant chemotherapy in group 1 and 2 were 39.1% and 68.6%, respectively. Amongst group 1 patients, adjuvant chemotherapy was not an independent risk factor for OS and CSS. Amongst group 2 patients, high-grade histologic findings and receiving sublobar resection were two risk factors for poorer survival. Adjuvant chemotherapy was also associated with an OS (adjusted hazard ratio (aHR), 0.52; 95% confidence interval (CI), 0.38-0.72; PConclusionFor patients with T2aN0 stage IB lung adenocarcinoma, adjuvant chemotherapy improved OS and CSS in those with tumors >3 cm, but
- Published
- 2023